Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;27(2):308-317.
doi: 10.1111/ene.14079. Epub 2019 Sep 30.

A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary

V Papp  1 , A Iljicsov  2 , C Rajda  3 , M Magyari  4 , N Koch-Henriksen  4   5 , T Petersen  1 , G Jakab  6 , I Deme  7 , F Nagy  7 , P Imre  8 , Z Lohner  9 , K Kovács  10 , A J Birkás  11 , Á Köves  12 , G Rum  13 , Z Nagy  14 , L Kerényi  15 , L Vécsei  3   16 , K Bencsik  3 , Z Jobbágy  17 , P Diószeghy  18 , L Horváth  19 , G Galántai  20 , J Kasza  21 , G Molnár  22 , M Simó  2 , M Sátori  23 , C Rózsa  24 , P Ács  25 , T Berki  26 , G Lovas  24 , S Komoly  25 , Z Illes  27   28
Affiliations

A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary

V Papp et al. Eur J Neurol. 2020 Feb.

Abstract

Background and purpose: The goal of this study was to determine the prevalence and incidence of neuromyelitis optica spectrum disorder (NMOSD) in Hungary based on the 2015 International Panel of NMO Diagnosis (IPND) criteria.

Methods: A retrospective population-based cohort study was conducted of 6.4 million Hungarians (age ≥ 16 years) between 1 January 2006 and 31 December 2016. Possible NMOSD patients were selected via multistage re-evaluation from multiple sources. Crude and sex- and serostatus-specific prevalence (per 100 000 persons) and incidence rates (per 1 000 000 person-years) from 2006 to 2015 were estimated and age-adjusted rates were determined.

Results: Of 2262 study candidates, 154 NMOSD patients (age ≥ 16 years) with onset until 31 December 2016 were identified based on 2015 IPND criteria. The prevalence analysis on 1 January 2016 included 123 NMOSD living cases, resulting in a prevalence of 1.91 [95% confidence interval (CI) 1.52-2.28] per 100 000 persons. The 101 incident cases emerging from the observed 76 394 288 person-years provided an incidence rate of 1.32 (95% CI 1.08-1.61) per 1 000 000 person-years. Age-adjusted prevalence was 1.87 (95% CI 1.56-2.23) per 100 000 persons and incidence was 1.20 (95% CI 0.98-1.46) per 1 000 000 person-years.

Conclusions: In this first report of a large population-based epidemiological study from an Eastern European Caucasian population using robust case validation, a greater prevalence and incidence of NMOSD was found compared to previous large studies in Caucasian populations.

Keywords: IPND; AQP4; incidence; neuromyelitis optica; population-based; prevalence.

PubMed Disclaimer

References

    1. Lennon PVA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
    1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
    1. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
    1. Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017; 88: 632-638.
    1. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; 79: 775-783.

Publication types

LinkOut - more resources